Maryland PDAB Moves Closer To UPLs, Suggests Other Policies To Pair

By Luke Zarzecki / October 2, 2025 at 6:07 PM

The Maryland Prescription Drug Affordability Board (PDAB) directed its staff not only to further develop policies on upper payment limits for Boehringer Ingelheim’s Jardiance and AstraZeneca’s Farxiga, but also other policies to bring drug costs down in the state.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.